PKI - PerkinElmer Stock Price, News & Analysis

$73.04 -0.22 (-0.30 %)
(As of 11/24/2017 03:10 PM ET)
Previous Close$73.26
Today's Range$72.85 - $73.31
52-Week Range$50.09 - $73.43
Volume325,700 shs
Average Volume634,127 shs
Market Capitalization$8.05 billion
P/E Ratio26.27
Dividend Yield0.38%
Beta0.77

About PerkinElmer (NYSE:PKI)

PerkinElmer logoPerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.


Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
SymbolNYSE:PKI
CUSIP71404610

Debt

Debt-to-Equity Ratio0.44%
Current Ratio2.59%
Quick Ratio2.09%

Price-To-Earnings

Trailing P/E Ratio26.27
Forward P/E Ratio25.36
P/E Growth2.18

Sales & Book Value

Annual Sales$2.12 billion
Price / Sales3.81
Cash Flow$3.55 per share
Price / Cash20.58
Book Value$23.01 per share
Price / Book3.17

Dividend

Annual Dividend$0.28
Dividend Yield0.4%

Profitability

Trailing EPS$3.60
Net Income$234.29 million
Net Margins18.27%
Return on Equity13.11%
Return on Assets6.82%

Miscellaneous

Employees8,000
Outstanding Shares110,220,000

Frequently Asked Questions for PerkinElmer (NYSE:PKI)

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Friday, October 27th. Shareholders of record on Friday, January 19th will be given a dividend of $0.07 per share on Friday, February 9th. This represents a $0.28 annualized dividend and a yield of 0.38%. The ex-dividend date of this dividend is Thursday, January 18th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings data on Thursday, May, 5th. The medical research company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.51 by $0.05. The medical research company had revenue of $538.70 million for the quarter, compared to analyst estimates of $532.55 million. PerkinElmer had a return on equity of 13.11% and a net margin of 18.27%. PerkinElmer's revenue was up 2.2% compared to the same quarter last year. During the same period in the prior year, the company posted $0.50 earnings per share. View PerkinElmer's Earnings History.

When will PerkinElmer make its next earnings announcement?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, January, 31st 2018. View Earnings Estimates for PerkinElmer.

Where is PerkinElmer's stock going? Where will PerkinElmer's stock price be in 2017?

15 analysts have issued 12 month price targets for PerkinElmer's stock. Their predictions range from $48.00 to $81.00. On average, they anticipate PerkinElmer's stock price to reach $68.23 in the next twelve months. View Analyst Ratings for PerkinElmer.

What are Wall Street analysts saying about PerkinElmer stock?

Here are some recent quotes from research analysts about PerkinElmer stock:

  • 1. According to Zacks Investment Research, "PerkinElmer holds ground on a strong global foothold, courtesy of its impending acquisition of Germany-based EUROIMMUN and takeover of India-based Tulip Diagnostics. The company continues to offer a global diagnostics portfolio focused on reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests. With an enhanced focus on product innovation and expansion into emerging markets, PerkinElmer has considerable potential upside. PerkinElmer delivered a solid first quarter, beating the Zacks Consensus Estimate on both the counts. The quarter witnessed solid organic revenue growth across all the business segments. Furthermore, a positive guidance instills our confidence on the stock. On the flipside, despite having a solid portfolio, unfavorable foreign exchange is a primary concern for PerkinElmer. Furthermore, PerkinElmer’s share price movement in the past one year has been unsatisfactory." (8/1/2017)
  • 2. Cantor Fitzgerald analysts commented, "Newborn screening in China continues to drive strong diagnostic growth, despite a slight decline in the Haoyuan nucleic acid testing. Diagnostic revenue in China was up more than 20% y/y in 1Q17. Despite a slight moderation in birth rates, uptake of the automated Genetic Screening Processor (GSP) has driven menu expansion. The company reports that 20-25% of the market is now screening for ~20 disorders, while the remaining 80% is screening for 2-4 disorders. India, the largest newborn screening opportunity with an estimated 26M annual births, continues to be relatively unpenetrated, but we do not anticipate a steep adoption ramp as the company experienced in China. Increase in reported revenue guidance leaves organic growth unchanged. The company raised its 2017 revenue guidance to $2.200-2.220B from $2.19-2.20B, implying 4-5% y/y reported revenue growth, compared with our prior estimate of $2.199B. Notably, the 4% organic revenue growth rate is unchanged, and the company expects a slightly lower FX headwind for 2017." (5/5/2017)

Who are some of PerkinElmer's key competitors?

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:

  • Robert F. Friel, Chairman of the Board, President, Chief Executive Officer
  • Frank Anders Wilson CPA, Chief Financial Officer, Senior Vice President
  • Deborah Butters, Chief Human Resource Officer, Senior Vice President
  • James L. Corbett, Executive Vice President and President - Discovery & Analytical Solutions
  • Joel S. Goldberg, Senior Vice President - Administration, General Counsel, Secretary
  • Prahlad R. Singh, Senior Vice President and President - Diagnostics
  • Daniel R. Tereau, Senior Vice President, Strategy and Business Development
  • Andrew Okun, Chief Accounting Officer, Vice President
  • Alexis P. Michas, Lead Independent Director
  • Pascale Witz, Director
  • , Bio & Compensation - 

Who owns PerkinElmer stock?

PerkinElmer's stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (5.59%), Pictet Asset Management Ltd. (2.67%), King Luther Capital Management Corp (2.33%), Victory Capital Management Inc. (1.33%), Ameriprise Financial Inc. (0.87%) and Bank of New York Mellon Corp (0.85%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, James Corbett, Joel S Goldberg, Kenton J Sicchitano, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Institutional Ownership Trends for PerkinElmer.

Who sold PerkinElmer stock? Who is selling PerkinElmer stock?

PerkinElmer's stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Victory Capital Management Inc., Janus Henderson Group PLC, Edinburgh Partners Ltd, Sector Gamma AS, Systematic Financial Management LP, California State Teachers Retirement System and Stevens Capital Management LP. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh, Robert F Friel and Vicki L Sato. View Insider Buying and Selling for PerkinElmer.

Who bought PerkinElmer stock? Who is buying PerkinElmer stock?

PerkinElmer's stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Robecosam AG, Russell Investments Group Ltd., Ameriprise Financial Inc., Schroder Investment Management Group, First Trust Advisors LP, Impax Asset Management LTD and OxFORD Asset Management LLP. View Insider Buying and Selling for PerkinElmer.

How do I buy PerkinElmer stock?

Shares of PerkinElmer can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PerkinElmer stock can currently be purchased for approximately $73.04.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $8.05 billion and generates $2.12 billion in revenue each year. The medical research company earns $234.29 million in net income (profit) each year or $3.60 on an earnings per share basis. PerkinElmer employs 8,000 workers across the globe.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at ir@perkinelmer.com.


MarketBeat Community Rating for PerkinElmer (PKI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  285 (Vote Outperform)
Underperform Votes:  300 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for PerkinElmer (NYSE:PKI)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $68.23 (6.58% downside)

Consensus Price Target History for PerkinElmer (NYSE:PKI)

Price Target History for PerkinElmer (NYSE:PKI)

Analysts' Ratings History for PerkinElmer (NYSE:PKI)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017Morgan StanleyBoost Price TargetOverweight$77.00 -> $78.00N/AView Rating Details
11/3/2017Robert W. BairdBoost Price TargetOutperform$75.00 -> $78.00N/AView Rating Details
10/20/2017Jefferies Group LLCReiterated RatingHold$70.00N/AView Rating Details
9/26/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral -> Neutral$67.00LowView Rating Details
9/26/2017Citigroup Inc.Reiterated RatingBuy$74.00 -> $80.00LowView Rating Details
9/1/2017Cowen IncReiterated RatingHold$70.00LowView Rating Details
8/4/2017Piper Jaffray CompaniesReiterated RatingBuy$81.00MediumView Rating Details
7/16/2017Cantor FitzgeraldReiterated RatingHoldLowView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market Perform$72.00LowView Rating Details
6/22/2017Evercore ISIReiterated RatingIn-Line$62.50 -> $68.00LowView Rating Details
5/6/2017Barclays PLCSet Price TargetSell$55.00LowView Rating Details
3/27/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
2/3/2017Bank of America CorporationDowngradeNeutral -> Underperform$48.00N/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$55.00N/AView Rating Details
8/5/2016J P Morgan Chase & CoBoost Price TargetNeutral$52.00 -> $55.00N/AView Rating Details
8/5/2016MizuhoDowngradeBuy -> Neutral$56.00N/AView Rating Details
5/6/2016Stifel NicolausBoost Price TargetBuy$51.00 -> $59.00N/AView Rating Details
12/3/2015WedbushDowngradeOutperform -> Neutral$56.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for PerkinElmer (NYSE:PKI)

Earnings by Quarter for PerkinElmer (NYSE:PKI)

Earnings History by Quarter for PerkinElmer (NYSE PKI)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018N/AView Earnings Details
8/3/2017Q2 2017$0.67$0.67$554.14 million$547.00 millionViewListenView Earnings Details
5/4/2017Q1 2017$0.54$0.55$506.81 million$514.12 millionViewListenView Earnings Details
11/7/2016Q3$0.66$0.68$572.03 million$548.00 millionViewListenView Earnings Details
5/5/2016Q116$0.51$0.56$532.55 million$538.70 millionViewN/AView Earnings Details
11/5/2015Q315$0.60$0.60$554.88 million$563.00 millionViewN/AView Earnings Details
7/30/2015Q2$0.59$0.60$555.66 million$564.00 millionViewListenView Earnings Details
4/30/2015Q115$0.46$0.50$537.27 million$526.90 millionViewN/AView Earnings Details
1/29/2015Q414$0.78$0.85$602.35 million$608.60 millionViewN/AView Earnings Details
10/30/2014Q3$0.57$0.67$550.40 million$542.05 millionViewListenView Earnings Details
8/7/2014Q2$0.59$0.59$572.26 million$556.20 millionViewListenView Earnings Details
4/24/2014Q114$0.44$0.46$531.31 million$531.90 millionViewListenView Earnings Details
1/30/2014Q413$0.70$0.73$588.95 million$594.00 millionViewListenView Earnings Details
10/30/2013Q313$0.48$0.49$523.84 million$524.30 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.48$0.51$532.95 million$543.30 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.48$0.36$532.25 million$505.38 millionViewListenView Earnings Details
1/31/2013Q4 2012$0.65$0.65$577.94 million$577.00 millionViewListenView Earnings Details
10/25/2012$0.44$0.45ViewN/AView Earnings Details
8/2/2012$0.47$0.53ViewN/AView Earnings Details
4/26/2012$0.41$0.43ViewN/AView Earnings Details
2/2/2012$0.51$0.62ViewN/AView Earnings Details
11/3/2011$0.39$0.41ViewN/AView Earnings Details
8/4/2011$0.40$0.42ViewN/AView Earnings Details
5/5/2011$0.31$0.34ViewN/AView Earnings Details
2/3/2011$0.41$0.44ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for PerkinElmer (NYSE:PKI)
2017 EPS Consensus Estimate: $2.94
2018 EPS Consensus Estimate: $3.50
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.60$0.60$0.60
Q2 20171$0.67$0.67$0.67
Q3 20171$0.73$0.73$0.73
Q4 20171$0.94$0.94$0.94
Q1 20181$0.80$0.80$0.80
Q2 20181$0.85$0.85$0.85
Q3 20181$0.87$0.87$0.87
Q4 20181$0.98$0.98$0.98
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for PerkinElmer (NYSE:PKI)

Next Dividend:2/9/2018
Annual Dividend:$0.28
Dividend Yield:0.38%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:7.78% (Trailing 12 Months of Earnings)
9.72% (Based on This Year's Estimates)
8.86% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for PerkinElmer (NYSE:PKI)

Dividend History by Quarter for PerkinElmer (NYSE PKI)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017quarterly$0.070.39%1/18/20181/19/20182/9/2018
7/24/2017quarterly$0.070.41%10/19/201710/20/201711/10/2017
4/28/2017quarterly$0.070.47%7/19/20177/21/20178/10/2017
1/27/2017quarterly$0.070.54%4/11/20174/14/20175/10/2017
10/26/2016quarterly$0.070.55%1/18/20171/20/20172/10/2017
7/27/2016quarterly$0.070.5%10/12/201610/14/201611/10/2016
4/25/2016quarterly$0.070.55%7/13/20167/15/20168/10/2016
1/28/2016quarterly$0.070.58%4/13/20164/15/20165/10/2016
10/29/2015quarterly$0.070.54%1/13/20161/15/20162/10/2016
7/23/2015quarterly$0.070.55%10/14/201510/16/201511/10/2015
4/27/2015quarterly$0.070.54%7/15/20157/17/20158/10/2015
1/23/2015quarterly$0.070.63%4/15/20154/17/20155/11/2015
10/23/2014quarterly$0.070.67%1/14/20151/16/20152/6/2015
7/24/2014quarterly$0.070.59%10/15/201410/17/201411/7/2014
4/22/2014quarterly$0.070.63%7/16/20147/18/20148/8/2014
1/24/2014quarterly$0.070.68%4/15/20144/18/20145/9/2014
10/24/2013quarterly$0.070.73%1/15/20141/17/20142/7/2014
7/26/2013quarterly$0.070.82%10/16/201310/18/201311/8/2013
6/13/2013quarterly$0.070.85%7/17/20137/19/20138/9/2013
1/25/2013quarterly$0.070.79%4/17/20134/19/20135/10/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PerkinElmer (NYSE PKI)

Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 90.49%
Insider Trades by Quarter for PerkinElmer (NYSE:PKI)
Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Insider Trades by Quarter for PerkinElmer (NYSE PKI)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/13/2017Peter BarrettDirectorSell7,071$71.07$502,535.97View SEC Filing  
11/7/2017Nicholas A LopardoDirectorSell24,050$70.72$1,700,816.00View SEC Filing  
6/19/2017Andrew OkunInsiderSell4,358$65.00$283,270.00View SEC Filing  
6/1/2017Peter BarrettDirectorSell10,000$63.22$632,200.00View SEC Filing  
5/15/2017Patrick J SullivanDirectorSell6,628$62.59$414,846.52View SEC Filing  
5/4/2017Robert F FrielInsiderSell25,100$60.00$1,506,000.00View SEC Filing  
4/27/2017Robert F FrielInsiderSell124,837$60.11$7,503,952.07View SEC Filing  
3/20/2017Andrew OkunInsiderSell3,000$57.27$171,810.00View SEC Filing  
3/13/2017Joel S GoldbergInsiderSell30,710$55.45$1,702,869.50View SEC Filing  
2/21/2017Alexis P. MichasDirectorSell8,308$55.60$461,924.80View SEC Filing  
2/15/2017Prahlad R SinghInsiderSell9,576$55.00$526,680.00View SEC Filing  
2/9/2017Daniel R TereauInsiderSell5,001$53.16$265,853.16View SEC Filing  
2/9/2017Vicki L SatoDirectorSell8,308$54.01$448,715.08View SEC Filing  
2/6/2017Daniel R TereauInsiderSell4,069$52.01$211,628.69View SEC Filing  
12/1/2016Alexis P. MichasDirectorSell15,000$51.00$765,000.00View SEC Filing  
9/22/2016Joel S GoldbergInsiderSell38,095$55.00$2,095,225.00View SEC Filing  
9/12/2016Daniel R TereauInsiderSell18,866$52.00$981,032.00View SEC Filing  
8/24/2016Kenton J SicchitanoDirectorSell15,189$54.87$833,420.43View SEC Filing  
8/17/2016Patrick J SullivanDirectorSell8,308$54.74$454,779.92View SEC Filing  
6/2/2016Alexis P MichasDirectorSell1,953$54.85$107,122.05View SEC Filing  
5/24/2016Robert F FrielCEOSell128,300$55.01$7,057,783.00View SEC Filing  
5/16/2016Robert F FrielCEOSell109,000$55.01$5,996,090.00View SEC Filing  
5/11/2016Robert F FrielCEOSell10,685$55.01$587,781.85View SEC Filing  
5/10/2016Vicki L SatoDirectorSell12,586$54.51$686,062.86View SEC Filing  
5/6/2016Robert F FrielCEOSell4,116$55.00$226,380.00View SEC Filing  
4/18/2016Daniel R TereauInsiderSell2,158$50.79$109,604.82View SEC Filing  
3/21/2016James CorbettInsiderSell1,723$48.74$83,979.02View SEC Filing  
2/24/2016Alexis P. MichasDirectorSell10,000$47.56$475,600.00View SEC Filing  
12/3/2015Kenton J SicchitanoDirectorSell10,216$51.05$521,526.80View SEC Filing  
11/3/2015Frank Anders WilsoninsiderSell16,380$52.69$863,062.20View SEC Filing  
10/23/2015Andrew OkunInsiderSell2,000$50.00$100,000.00View SEC Filing  
9/14/2015James CorbettInsiderSell3,000$47.59$142,770.00View SEC Filing  
9/3/2015Kenton J. SicchitanoDirectorSell12,586$47.88$602,617.68View SEC Filing  
6/5/2015Alexis P MichasDirectorSell20,000$52.25$1,045,000.00View SEC Filing  
6/3/2015Frank Anders WilsonInsiderSell16,380$52.60$861,588.00View SEC Filing  
3/27/2015Joel S GoldbergInsiderSell10,646$51.00$542,946.00View SEC Filing  
3/23/2015Andrew OkunInsiderSell2,000$50.09$100,180.00View SEC Filing  
3/20/2015James CorbettInsiderSell5,157$50.23$259,036.11View SEC Filing  
3/18/2015Joel S GoldbergInsiderSell9,000$49.00$441,000.00View SEC Filing  
3/6/2015Patrick J SullivanDirectorSell12,586$46.90$590,283.40View SEC Filing  
3/5/2015Alexis P MichasDirectorSell8,892$47.00$417,924.00View SEC Filing  
3/5/2015Joel S GoldbergInsiderSell9,000$47.00$423,000.00View SEC Filing  
2/10/2015Vicki L SatoDirectorSell24,000$45.55$1,093,200.00View SEC Filing  
2/9/2015Andrew OkunInsiderSell6,262$45.82$286,924.84View SEC Filing  
2/3/2015Nicholas A LopardoDirectorSell8,892$46.30$411,699.60View SEC Filing  
2/3/2015Robert F FrielCEOSell60,709$46.26$2,808,398.34View SEC Filing  
2/2/2015Robert F FrielCEOSell319,065$46.02$14,683,371.30View SEC Filing  
11/14/2014James C MullenDirectorSell8,892$43.73$388,847.16View SEC Filing  
11/13/2014Patrick J SullivanDirectorSell8,892$43.46$386,446.32View SEC Filing  
9/4/2014Kenton J SicchitanoDirectorSell8,892$44.98$399,962.16View SEC Filing  
7/2/2014Daniel R MarshakSVPSell12,000$48.00$576,000.00View SEC Filing  
6/26/2014Daniel R MarshakSVPSell10,000$46.60$466,000.00View SEC Filing  
6/19/2014James CorbettInsiderSell57,126$46.69$2,667,212.94View SEC Filing  
6/9/2014Maurice H TenneyInsiderSell5,504$47.26$260,119.04View SEC Filing  
6/9/2014Robert F FrielCEOSell124,858$46.70$5,830,868.60View SEC Filing  
6/5/2014Alexis P MichasDirectorSell9,146$46.30$423,459.80View SEC Filing  
6/2/2014Alexis P MichasDirectorSell5,854$45.00$263,430.00View SEC Filing  
6/2/2014Joel S GoldbergInsiderSell17,000$45.11$766,870.00View SEC Filing  
5/12/2014Alexis MichasDirectorSell5,000$44.40$222,000.00View SEC Filing  
4/29/2014Nicholas LopardoDirectorSell12,951$41.98$543,682.98View SEC Filing  
4/7/2014James CorbettInsiderSell22,027$45.11$993,637.97View SEC Filing  
3/12/2014Daniel MarshakSVPSell19,292$45.29$873,734.68View SEC Filing  
3/11/2014John LetcherSVPSell41,000$45.40$1,861,400.00View SEC Filing  
3/7/2014Andrew OkunCAOSell9,398$46.35$435,597.30View SEC Filing  
2/27/2014Alexis MichasDirectorSell5,000$45.25$226,250.00View SEC Filing  
2/14/2014Vicki SatoDirectorSell21,843$43.97$960,436.71View SEC Filing  
2/7/2014James MullenDirectorSell12,951$43.73$566,347.23View SEC Filing  
12/13/2013Maurice TenneyInsiderSell25,000$38.91$972,750.00View SEC Filing  
12/10/2013Daniel MarshakSVPSell12,183$39.59$482,324.97View SEC Filing  
11/14/2013Robert FrielCEOSell112,461$37.14$4,176,801.54View SEC Filing  
9/10/2013Robert F FrielCEOSell141,000$37.45$5,280,450.00View SEC Filing  
9/6/2013Andrew OkunCAOSell6,805$36.86$250,832.30View SEC Filing  
5/1/2013Alexis P MichasDirectorSell6,440$30.85$198,674.00View SEC Filing  
4/30/2013James C MullenDirectorSell6,440$30.31$195,196.40View SEC Filing  
4/11/2013Maurice H TenneyInsiderSell9,500$35.00$332,500.00View SEC Filing  
9/13/2012Robert F FrielCEOSell50,565$29.00$1,466,385.00View SEC Filing  
8/9/2012Kenton J SicchitanoDirectorSell9,454$27.93$264,050.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for PerkinElmer (NYSE PKI)

Source:
DateHeadline
PerkinElmer (PKI) a Buy on Healthy Earnings Growth - Investorplace.comPerkinElmer (PKI) a Buy on Healthy Earnings Growth - Investorplace.com
investorplace.com - November 23 at 5:41 PM
PerkinElmer (PKI) a Buy on Healthy Earnings GrowthPerkinElmer (PKI) a Buy on Healthy Earnings Growth
investorplace.com - November 23 at 12:21 PM
PerkinElmer to Present at Citi Global Healthcare ConferencePerkinElmer to Present at Citi Global Healthcare Conference
finance.yahoo.com - November 22 at 6:42 AM
New Research Coverage Highlights Houghton Mifflin Harcourt, PerkinElmer, Stanley Black & Decker, PVH, BankUnited, and ViewRay — Consolidated Revenues, Company Growth, and Expectations for 2018New Research Coverage Highlights Houghton Mifflin Harcourt, PerkinElmer, Stanley Black & Decker, PVH, BankUnited, and ViewRay — Consolidated Revenues, Company Growth, and Expectations for 2018
finance.yahoo.com - November 21 at 9:21 AM
PerkinElmer’s (PKI) Healthy Quant Score Keep it a BuyPerkinElmer’s (PKI) Healthy Quant Score Keep it a Buy
investorplace.com - November 16 at 12:51 PM
PerkinElmer, Inc. (PKI) Director Sells $502,535.97 in StockPerkinElmer, Inc. (PKI) Director Sells $502,535.97 in Stock
www.americanbankingnews.com - November 14 at 4:32 PM
PerkinElmer, Inc. (PKI) Expected to Announce Quarterly Sales of $616.73 MillionPerkinElmer, Inc. (PKI) Expected to Announce Quarterly Sales of $616.73 Million
www.americanbankingnews.com - November 14 at 4:50 AM
Jefferies Group Weighs in on PerkinElmer, Inc.s FY2017 Earnings (PKI)Jefferies Group Weighs in on PerkinElmer, Inc.'s FY2017 Earnings (PKI)
www.americanbankingnews.com - November 13 at 2:36 AM
Contrasting PerkinElmer (PKI) and Its PeersContrasting PerkinElmer (PKI) and Its Peers
www.americanbankingnews.com - November 12 at 11:54 PM
 Brokerages Expect PerkinElmer, Inc. (PKI) Will Post Earnings of $0.94 Per Share Brokerages Expect PerkinElmer, Inc. (PKI) Will Post Earnings of $0.94 Per Share
www.americanbankingnews.com - November 12 at 7:12 PM
Financial Review: PerkinElmer (PKI) versus Its PeersFinancial Review: PerkinElmer (PKI) versus Its Peers
www.americanbankingnews.com - November 10 at 3:10 AM
Earnings Momentum Keep PerkinElmer (PKI) a BuyEarnings Momentum Keep PerkinElmer (PKI) a Buy
investorplace.com - November 9 at 1:49 PM
Perkinelmer Earns Relative Strength Rating Upgrade; Hits Key ThresholdPerkinelmer Earns Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - November 9 at 11:34 AM
PerkinElmer, Inc. (PKI) Director Nicholas A. Lopardo Sells 24,050 SharesPerkinElmer, Inc. (PKI) Director Nicholas A. Lopardo Sells 24,050 Shares
www.americanbankingnews.com - November 8 at 6:32 PM
PerkinElmer, Inc. (PKI) PT Raised to $78.00 at Morgan StanleyPerkinElmer, Inc. (PKI) PT Raised to $78.00 at Morgan Stanley
www.americanbankingnews.com - November 5 at 7:42 AM
Robert W. Baird Boosts PerkinElmer, Inc. (PKI) Price Target to $78.00Robert W. Baird Boosts PerkinElmer, Inc. (PKI) Price Target to $78.00
www.americanbankingnews.com - November 5 at 7:42 AM
PerkinElmer (United States) (PKI) Q3 2017 Results - Earnings Call TranscriptPerkinElmer (United States) (PKI) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 4 at 9:41 PM
PerkinElmer Announces Financial Results for the Third Quarter of 2017PerkinElmer Announces Financial Results for the Third Quarter of 2017
finance.yahoo.com - November 4 at 9:41 PM
PerkinElmer beats Street 3Q forecastsPerkinElmer beats Street 3Q forecasts
finance.yahoo.com - November 4 at 9:41 PM
PerkinElmer third quarter profit edges past Street forecastPerkinElmer third quarter profit edges past Street forecast
finance.yahoo.com - November 4 at 9:41 PM
Edited Transcript of PKI earnings conference call or presentation 2-Nov-17 9:00pm GMTEdited Transcript of PKI earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 4 at 9:41 PM
Validea Peter Lynch Strategy Daily Upgrade Report - 11/4/2017 - NasdaqValidea Peter Lynch Strategy Daily Upgrade Report - 11/4/2017 - Nasdaq
www.nasdaq.com - November 4 at 8:54 AM
PerkinElmer (PKI) Beats Q3 Earnings, Updates 17 Guidance - NasdaqPerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance - Nasdaq
www.nasdaq.com - November 4 at 8:53 AM
PerkinElmer, Inc. (PKI) Given Consensus Recommendation of "Hold" by AnalystsPerkinElmer, Inc. (PKI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 2 at 12:18 PM
Quant Score Keeps PerkinElmer (PKI) a BuyQuant Score Keeps PerkinElmer (PKI) a Buy
investorplace.com - November 2 at 12:07 PM
PerkinElmer Demonstrates the Benefits of High Throughput Screening Platforms to Interrogate Physiologically Relevant ModelsPerkinElmer Demonstrates the Benefits of High Throughput Screening Platforms to Interrogate Physiologically Relevant Models
www.marketwatch.com - November 2 at 7:45 AM
Key Factors to Influence PerkinElmers (PKI) Q3 EarningsKey Factors to Influence PerkinElmer's (PKI) Q3 Earnings
finance.yahoo.com - November 2 at 7:45 AM
Key Factors to Influence PerkinElmer's (PKI) Q3 EarningsKey Factors to Influence PerkinElmer's (PKI) Q3 Earnings
finance.yahoo.com - November 2 at 7:45 AM
Phase II Clinical Trial Data Establishes Effectiveness of using a Child’s Own Cord Blood to Treat Cerebral PalsyPhase II Clinical Trial Data Establishes Effectiveness of using a Child’s Own Cord Blood to Treat Cerebral Palsy
finance.yahoo.com - October 31 at 4:22 PM
PerkinElmer Elects Pascale Witz to its Board of DirectorsPerkinElmer Elects Pascale Witz to its Board of Directors
finance.yahoo.com - October 31 at 7:58 AM
PerkinElmer, Inc. to Issue Quarterly Dividend of $0.07 (PKI)PerkinElmer, Inc. to Issue Quarterly Dividend of $0.07 (PKI)
www.americanbankingnews.com - October 27 at 6:50 PM
PerkinElmer Board Declares Quarterly DividendPerkinElmer Board Declares Quarterly Dividend
finance.yahoo.com - October 27 at 4:45 PM
Strong Quant Score Keeps PerkinElmer (PKI) a BuyStrong Quant Score Keeps PerkinElmer (PKI) a Buy
investorplace.com - October 26 at 12:10 PM
$552.38 Million in Sales Expected for PerkinElmer, Inc. (PKI) This Quarter$552.38 Million in Sales Expected for PerkinElmer, Inc. (PKI) This Quarter
www.americanbankingnews.com - October 25 at 11:01 AM
ETFs with exposure to PerkinElmer, Inc. (United States) : October 23, 2017ETFs with exposure to PerkinElmer, Inc. (United States) : October 23, 2017
finance.yahoo.com - October 24 at 8:31 AM
PerkinElmers (PKI) Buy Rating Reaffirmed at Robert W. BairdPerkinElmer's (PKI) Buy Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - October 21 at 11:52 PM
Jefferies Group LLC Reiterates Hold Rating for PerkinElmer, Inc. (PKI)Jefferies Group LLC Reiterates Hold Rating for PerkinElmer, Inc. (PKI)
www.americanbankingnews.com - October 21 at 5:26 PM
Luna Innovations (LUNA) vs. PerkinElmer (PKI) Critical ReviewLuna Innovations (LUNA) vs. PerkinElmer (PKI) Critical Review
www.americanbankingnews.com - October 21 at 4:24 AM
PerkinElmer (PKI) Upgraded to Buy on Superior Quant ScorePerkinElmer (PKI) Upgraded to Buy on Superior Quant Score
investorplace.com - October 19 at 12:07 PM
PerkinElmer, Inc. (PKI) Receives Average Rating of "Hold" from BrokeragesPerkinElmer, Inc. (PKI) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - October 8 at 9:00 AM
PerkinElmers (PKI) "Overweight" Rating Reiterated at Morgan StanleyPerkinElmer's (PKI) "Overweight" Rating Reiterated at Morgan Stanley
www.americanbankingnews.com - October 7 at 12:00 PM
PerkinElmer to Hold Earnings Call on Thursday, November 2, 2017PerkinElmer to Hold Earnings Call on Thursday, November 2, 2017
finance.yahoo.com - October 7 at 7:24 AM
 Brokerages Anticipate PerkinElmer, Inc. (PKI) Will Post Quarterly Sales of $552.30 Million Brokerages Anticipate PerkinElmer, Inc. (PKI) Will Post Quarterly Sales of $552.30 Million
www.americanbankingnews.com - October 6 at 1:16 AM
ETFs with exposure to PerkinElmer, Inc. (United States) : October 3, 2017ETFs with exposure to PerkinElmer, Inc. (United States) : October 3, 2017
finance.yahoo.com - October 5 at 4:24 PM
PerkinElmer, Inc. (PKI) Expected to Post Earnings of $0.73 Per SharePerkinElmer, Inc. (PKI) Expected to Post Earnings of $0.73 Per Share
www.americanbankingnews.com - October 5 at 12:14 AM
PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 2, 2017PerkinElmer, Inc. (United States) :PKI-US: Earnings Analysis: Q2, 2017 By the Numbers : October 2, 2017
finance.yahoo.com - October 3 at 10:47 AM
Goldman Sachs Group, Inc. (The) Reiterates "Neutral" Rating for PerkinElmer, Inc. (PKI)Goldman Sachs Group, Inc. (The) Reiterates "Neutral" Rating for PerkinElmer, Inc. (PKI)
www.americanbankingnews.com - October 1 at 11:34 PM
PerkinElmer (PKI) Upgraded to Buy from a Hold - Investorplace.comPerkinElmer (PKI) Upgraded to Buy from a Hold - Investorplace.com
investorplace.com - September 29 at 10:57 PM
VWRs New Kitting Center in Czech Republic to Boost EMEA ArmVWR's New Kitting Center in Czech Republic to Boost EMEA Arm
finance.yahoo.com - September 29 at 5:54 PM
PerkinElmer (PKI) Upgraded to Buy from a HoldPerkinElmer (PKI) Upgraded to Buy from a Hold
investorplace.com - September 28 at 11:33 AM

Social Media

Financials

Chart

PerkinElmer (NYSE PKI) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.